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Bacteremia Due to Oral Viridans Streptococci in 
Neutropenic Patients with Cancer: Cytostatics Are a 
More Important Risk Factor than Antibacterial 
Prophylaxis
Sir— In their recent article Bochud et al. [1] stated that “ the 
fluoroquinolones are frequently used as prophylaxis for patients 
with cancer . . . and bacteremia due to these microorganisms 
has been observed under this prophylactic regimen.” They also 
stated that the problem o f  viridans streptococcal bacteremia 
. . is probably related to the use o f  quinolones as antibacte­
rial prophylaxis.” However, the references chosen to support 
these statements were incorrect since Cohen et al. [2] and Hens- 
lee et al. [3] reported that bacteremia developed exclusively 
while the patients were receiving co-trimoxazole prophylaxis, 
which was also the antimicrobial given to most o f  the patients 
described by Weisman et al. [4] and Elting et al. [5].
During 1986-1989, bacteremia due to oral viridans strepto­
cocci (OVS) developed in 94 (28%) of 341 neutropenic episodes 
that occurred in adults treated for hematologic malignancies at 
our center. Although both ciprofloxacin and co-trimoxazole 
plus colistin had been given as prophylaxis, bone marrow trans­
plant (BMT) recipients had all been given ciprofloxacin (table 
1), so the impact o f  each regimen on the development o f  OVS 
bacteremia could only be assessed for those treated with cyto­
static chemotherapy.
Bacteremia due to OVS occurred in 23 ( 14%) o f  168 neutro­
penic episodes in which co-trimoxazoie plus colistin had been 
given as prophylaxis compared with 16 (22%) of 74  episodes in 
which ciprofloxacin had been given (P = . 175 ; not significant). 
When the dose o f  cytarabine (cytosine arabinoside) is taken into 
account, the incidence o f  OVS bacteremia among those given 
>1 g/[m2 , d] was '"'30%, whether patients had received the 
quinolone or co-trimoxazole. In contrast, when a lower dose o f  
cytarabine or an altogether different regimen had been used, 
twice as many patients developed bacteremia after receiving 
prophylaxis with ciprofloxacin than did those who had received 
the alternative regimen, although the incidence was only one- 
half that observed with the higher dose o f  cytarabine. However,
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rates o f bacteremia, even after administration of the higher dose 
of cytarabine, were still markedly lower than that (56%) for 99 
allogeneic BMT recipients during the same period (P <  .001). 
This remarkably high rate was attributed to the occurrence of  
severe oromucositis as a result o f  using the more-intensive con­
ditioning regimen that included anthracyclines, particularly 
idarubicin [6], in conjunction with total body irradiation and 
cyclophosphamide [7]. Those patients who underwent condi­
tioning for transplantation without additional anthracyclines ex­
perienced a rate o f OVS bacteremia similar to that for patients 
treated with cytarabine {">1 g/[m2 • d]). Thus, the higher dose of 
cytarabine and, moreover, the use o f  idarubicin had a much 
greater influence on the development o f  OVS bacteremia than 
did the prophylactic regimen. Only when lower doses o f  cytara­
bine or other cytostatics were used did the negative impact of 
ciprofloxacin prophylaxis become clearer.
It is also o f interest that the majority of strains that were iso­
lated from BMT recipients and that could be adequately identi­
fied to the species level with use of the API Strep system 
(BioMerieux, Marcy l'Etoile, France) were identified as Strepto­
coccus oralis, while the majority o f  those isolated from non-BMT 
patients were Streptococcus mitis. This finding corresponds to 
that o f McWhinney et al, [8]. Idarubicin induces severe and
Table I. The impact o f  administering cytostatic regimens plus 
ciprofloxacin or co-trimoxazole on the development of bacteremia 
due to oral viridans streptococci in BMT recipients at University 
Hospital Nijmegen, 1986-1989,
P H M H
No. o f  patients receiving indicated 
prophylactic agent/total no. o f  patients 
receiving cytostatic chemotherapy (%)
M E H M f P M M M M M U M I 1 I I B I I I É H  |J  ilIJWWW
( y tostatie chemotherapy Ciprofloxacin Co-trimoxa/.ole/colistin
Allogeneic BMT conditioning
regimen
Idarubicin +  standard* 47/77(61) ■ • •
Standard only* 8/22(36) 1 4 1
Cytoreductive therapy with:
Cytarabine >  1 g /(m 2 -d) 1 2 /3 7 (3 2 ) 14/50 (28)
Cytarabine <  1 gAni1 • d) 2 /26  (8) 4/64 (6)
No cytarabine 2/11 (18) 5/54 (9)
Total 71/173 (41) 23/168 (13)
NOTE. BMT -  bone marrow transplant.
* The standard conditioning regimen is total body irradiation and eyclo 
phosphamide.
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protracted oromucositis in BMT recipients [7, 9] that is o f  quite 
a different character than the milder form induced by cytara- 
bine. In contrast, high doses o f  cytarabine can be profoundly 
toxic to the gut and lungs [ 10]. The colonization of the stomach 
or digestive tract might therefore provide the alternative portal 
o f  entry that Bochud and colleagues suggested. Extensive colon­
ization of the stomach and the small intestine would also be 
facilitated by any H2 antagonists used to manage the dyspepsia 
that frequently occurs following cytostatic chemotherapy.
The use o f  these agents was also implicated by Elting and 
associates [5] as a significant risk factor for the development of  
the so-called alpha strep shock syndrome. Moreover, patients 
with oromucositis tend to swallow large volumes of slimy 
mucus, which may assist in protecting the oral streptococci. 
Therefore, the presence o f  gastrointestinal colonization in pa­
tients with bacteremia due to S. mitis might explain why only a 
minority o f these patients go on to develop the alpha strep shock 
syndrome; the microbial load may well be sufficient to elicit the 
release of cytokines that are necessary to induce sepsis syn­
drome, adult respiratory distress syndrome, and, in some cases, 
fatal multiorgan failure.
J. Peter Donnelly, Ellen C. Dompeling, 
Jacques F. Meis, and Ben E. De Pauw
Departments o f  Microbiology and  Hematology, University Hospital
Nijmegen, Nijmegen, the Netherlands
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Reply
Sir— We agree with Donnelly et al. that bacteremia due to oral 
viridans streptococci (OVS) in neutropenic patients with cancer 
has occurred not only while the patients were receiving prophy­
laxis with fluoroquinolones but also while they were receiving 
other prophylactic antibiotic regimens. This finding was inad­
vertently omitted in our text but cited in the references. The 
interesting data of Donnelly et al. as well as data from other 
centers, including ours, clearly suggest that aggressive cytostatic 
chemotherapy is probably the key factor predisposing neutro­
penic patients to OVS bacteremia. However, it appears clear 
that several widely used prophylactic agents, including fluoro­
quinolones and co-trimoxazole, are not effective in preventing 
OVS bacteremia. Moreover, OVS bacteremia was practically un­
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known before the use o f  these prophylactic regimens, and two 
case-control studies have shown an association between the use 
ofquinolones or co-trimoxazole and the occurrence of OVS bac­
teremia [1, 2]. Thus, certain prophylactic antibiotics may not 
only be ineffective in preventing OVS bacteremia, but they may 
also alter the endogenous bacterial flora in a way that predis­
poses susceptible patients to the infection.
P.-Y. Bochud, Ph. Eggiman, Th. Calandra, G. Van Mclle, 
L. Saghafi, and P. Francioli
Division autonome de Médecine Préventive Hospitalière, Division des
Maladies Infectieuses, and Institut Universitaire de Médecine 
Sociale et Préventive, Centre Hospitalier Universitaire Vaudois,
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